Oxytocin
A peptide hormone used in FDA-approved medical settings but also frequently reframed in wellness and research-market discussions.
Also referenced as: Pitocin
This peptide maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Pitocin
FDA label signal · 1384 trials · 29240 PubMed results
Oxytocin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Oxytocin has 51 name-matched clinical trials (3 international) (highest phase: Phase 4) and 29253 PubMed-indexed publications and holds an FDA drug label. 16 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What oxytocin is
Oxytocin is a naturally occurring peptide hormone with established medical use in regulated clinical settings. It is also one of the few hormone peptides that people may recognize outside peptide-market culture.
Why it matters
It anchors the hormone category with a peptide that has legitimate clinical history rather than only research-market visibility.
Regulatory context
Oxytocin is associated with FDA-approved medical products and clinical use. That does not make every non-medical or retail framing of oxytocin equivalent to an approved use case.
Practical reading note
This is another case where the ingredient name alone is not enough. Formulation, indication, and clinical context matter.